Changchun High And New Technology Industries (Group) Inc(000661) : the impact and degree of centralized purchase on the company have not been determined

Changchun High And New Technology Industries (Group) Inc(000661) said on the investor interaction platform that at present, the bidding process for the centralized procurement of drugs has not been officially started. The specific impact on the company’s performance will also depend on the actual participation of kinsay pharmaceutical in the bidding, the winning result and the winning price. The impact and degree of impact of this centralized procurement on the company have not been determined. The company and kinsay pharmaceutical will formulate relevant plans on the premise of not violating laws and regulations based on the practical maintenance of the company’s interests. At present, the company’s growth hormone products include three kinds, specifically polyethylene glycol recombinant human growth hormone injection (long-acting water injection), recombinant human growth hormone injection (water injection) and recombinant human growth hormone for injection (powder injection).